Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05773326 · ClinicalTrials.gov registry record · Early Phase 1
Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG
A Early Phase 1 study of Glioblastoma and Glioma, sponsored by Nader Sanai.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT05773326 is a Early Phase 1 study of Glioblastoma and Glioma that is actively recruiting participants, run by Nader Sanai. The registered enrollment target is 12 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05773326, a Early Phase 1 study of Glioblastoma and Glioma, is actively recruiting participants, sponsored by Nader Sanai.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single-center, open-label, dose-escalating Phase 0 trial that will enroll participants with a confirmed diagnosed recurrent high-grade glioma (grade 3 or 4 per WHO criteria) targeting the mTOR pathway. Eligible participants will be administered a single infusion of temsirolimus through super-selective intra-arterial infusion or intravenous infusion. Participants will receive the study drug administration on the same day as the planned surgical resection of the tumor.
Conditions Studied
Interventions
- DRUG Temsirolimus
Study Locations (1)
Arizona
- St. Joseph's Hospital and Medical Center - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2023-05-15 |
| Est. Completion | 2028-05 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05773326
The ClinicalTrials.gov registry entry for NCT05773326 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (89% lower). The listed sponsor is Nader Sanai, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Glioblastoma appearing as the primary indexed condition, and to 1 intervention - of which Temsirolimus is the first listed.
NCT05773326 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT05773326 about?
NCT05773326 is a clinical study titled "Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG". This is a single-center, open-label, dose-escalating Phase 0 trial that will enroll participants with a confirmed diagnosed recurrent high-grade glioma (grade 3 or 4 per WHO criteria) targeting the mTOR pathway. Eligible participants will be administered a single infusion of temsirolimus through sup...
What is the current status of trial NCT05773326?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 12 participants. The study started on 2023-05-15. Estimated completion is 2028-05.
What conditions does trial NCT05773326 study?
This clinical trial studies the following conditions: Glioblastoma, Glioma, High Grade Glioma, Glioma, Malignant.
What interventions are being tested in trial NCT05773326?
The interventions under investigation include: Temsirolimus (DRUG).
Who is sponsoring clinical trial NCT05773326?
This trial is sponsored by Nader Sanai, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05773326 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
RECRUITING · Early Phase 1
-
Implantable Microdevice In Primary Brain Tumors
RECRUITING · Early Phase 1
-
A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions
RECRUITING · Early Phase 1
-
A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma
RECRUITING · Early Phase 1
-
Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma
RECRUITING · Early Phase 1
-
Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma
RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.